Syndivia and TVM Capital Life Science Announce Creation of Auricula Biosciences to Develop Innovative Therapy for Patients with K-Ras mutant malignancies

Luxembourg, January 13th, 2022 – TVM Life Science Innovation II SCSp announced the Fund’s investment establishing Auricula Biosciences, Inc., a company based in Wilmington, Delaware, USA.

Auricula Biosciences plans to develop a first-in-class targeted therapeutic for a broad set of K-Ras mutant malignancies to clinical proof-of-concept. This conjugate targets macropinocytosis, a unique feature of cancer cells harboring K-Ras mutations.

Full press release is available on TVM Capital Life Science website.